Latest Breaking News On - Euronext growth - Page 1 : comparemela.com

Cellectis S A : Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications 12 Jun 2024 22:30 CEST .

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications

NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell

AFTER THE SUCCESS OF ITS TEST PROGRAM, BOOSTHEAT STARTS A MONETIZING PROCESS FOR ITS HYBRID COMPRESSOR AND ADAPTS ITS ORGANIZATION

Vénissieux, 10 June 2024 BOOSTHEAT (ALBOO), a French industrial and software player in energy efficiency, announces the successful completion of the test program for its new hybrid compressor, marking

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia